>
Verve Therapeutics Inc logo

VERV - Verve Therapeutics Inc Share Price

$35.25 -1.8  -4.7%

Last Trade - 3:12pm

Sector
Healthcare
Size
Market Cap £26.56
Enterprise Value £n/a
Revenue £n/a
Position in Universe th / 6942
Bullish
Bearish
Unlock VERV Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 01st Jan 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : Verve Therapeutics Inc has not disclosed anycomparable financial information.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

VERV Revenue Unlock VERV Revenue

Net Income

VERV Net Income Unlock VERV Revenue

Normalised EPS

VERV Normalised EPS Unlock VERV Revenue

PE Ratio Range

VERV PE Ratio Range Unlock VERV Revenue

Dividend Yield Range

VERV Dividend Yield Range Unlock VERV Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
VERV EPS Forecasts Unlock VERV Revenue
Profile Summary

Verve Therapeutics, Inc. is a genetic medicines company. The Company is engaged in pioneering a new approach to the care of cardiovascular disease (CVD) transforming treatment from chronic management to single-course gene editing medicines. It is advancing a pipeline of single-course in vivo gene editing programs, each designed to mimic natural disease resistance mutations and turn off specific genes to lower blood lipids. The Company's initial two programs focuses on PCSK9 and ANGPTL3, two genes that regulate levels of blood lipids. Its pipeline of in vivo gene editing programs for atherosclerotic cardiovascular disease (ASCVD) includes VERVE-101 and ANGPTL3. The Company's lead product candidate, VERVE-101, is designed to be a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. Its second program is designed to permanently turn off the ANGPTL3 gene in the liver. ANGPTL3 is a key regulator of cholesterol and triglyceride metabolism.

Directors
Last Annual January 1st, 1970
Last Interim January 1st, 1970
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange NASDAQ Global Select Market
Shares in Issue
Free Float (0.0%)
Eligible for
× ISAs
SIPPs
VERV Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for VERV
Upcoming Events for VERV
Frequently Asked Questions for Verve Therapeutics Inc
What is the Verve Therapeutics Inc share price?

As of 3:12pm, shares in Verve Therapeutics Inc are trading at $35.25, giving the company a market capitalisation of £26.56. This share price information is delayed by 15 minutes.

How has the Verve Therapeutics Inc share price performed this year?

Shares in Verve Therapeutics Inc are currently trading at $35.25 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Verve Therapeutics Inc price has moved by % over the past year.

What are the analyst and broker recommendations for Verve Therapeutics Inc?

There are no analysts currently covering Verve Therapeutics Inc.

When will Verve Therapeutics Inc next release its financial results?

It is not known when Verve Therapeutics Inc will next release financial results.

What is the Verve Therapeutics Inc dividend yield?

Verve Therapeutics Inc does not currently pay a dividend.

Does Verve Therapeutics Inc pay a dividend?

Verve Therapeutics Inc does not currently pay a dividend.

When does Verve Therapeutics Inc next pay dividends?

Verve Therapeutics Inc does not currently pay a dividend.

How do I buy Verve Therapeutics Inc shares?

To buy shares in Verve Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Verve Therapeutics Inc?

Shares in Verve Therapeutics Inc are currently trading at $35.25, giving the company a market capitalisation of £26.56.

Where are Verve Therapeutics Inc shares listed? Where are Verve Therapeutics Inc shares listed?

Here are the trading details for Verve Therapeutics Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: VERV
What kind of share is Verve Therapeutics Inc?

We were not able to load our ranking data for Verve Therapeutics Inc

Is there a Verve Therapeutics Inc share price forecast 2021?

We were not able to load any forecast data for Verve Therapeutics Inc.

How can I tell whether the Verve Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Verve Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been %. At the current price of $35.25, shares in Verve Therapeutics Inc are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Verve Therapeutics Inc PE Ratio?

We were not able to find PE ratio data for Verve Therapeutics Inc.

Who are the key directors of Verve Therapeutics Inc?

Verve Therapeutics Inc's management team is headed by:

Burt Adelman - CHM
Andrew Ashe - PRE
Sekar Kathiresan - CEO
Andrew Bellinger - CSO
Maggie Beaudoin - SDR
Who are the major shareholders of Verve Therapeutics Inc?

Here are the top five shareholders of Verve Therapeutics Inc based on the size of their shareholding:

Casdin Capital, LLC Hedge Fund
Percentage owned: 2.28% (1,000k shares)
Kathiresan (Sekar M.D.) Individual Investor
Percentage owned: 1.29% (566k shares)
Adelman (Burt M.D.) Individual Investor
Percentage owned: 0.93% (410k shares)
Ashe (Andrew D) Individual Investor
Percentage owned: 0.38% (167k shares)
Similar to VERV
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.